Ontology highlight
ABSTRACT:
SUBMITTER: Micallef IN
PROVIDER: S-EPMC3204728 | biostudies-literature | 2011 Oct
REPOSITORIES: biostudies-literature
Micallef Ivana N M IN Maurer Matthew J MJ Wiseman Gregory A GA Nikcevich Daniel A DA Kurtin Paul J PJ Cannon Michael W MW Perez Domingo G DG Soori Gamini S GS Link Brian K BK Habermann Thomas M TM Witzig Thomas E TE
Blood 20110614 15
Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase 2 trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in untreated DLBCL. A secondary aim was to assess the efficacy of interim positron emission tomography (PET) to pre ...[more]